Methods of identifying compounds that modulate body weight using the OB receptor

• US 6,395,498 B1
• Filed: 05/28/1997
• Issued: 05/28/2002
• Est. Priority Date: 11/27/1995
• Status: Expired due to Fees

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: White, David W., Tepper, Robert I., Tartaglia, Louis A., Culpepper, Janice A.
• Primary Examiner(s): ULM, JOHN D
• Application Number:
  US08/864,564
• Time in Patent Office: 1,826 Days
• Field of Search: 435/7.1,7.2 438/69.1 536/23.5 436/501
• US Class Current: 435/7.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.

Claims

1. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO;

3 from nucleotide 194 to nucleotide 3688 under conditions of hybridization at 65°

C. in 0.5 M NaHPO₄, 7% SDS, and 1 mM EDTA followed by washing at 68°

C. in 0.1×

SSC and 0.1% SDS.

10. The method of any one of claims 1-9, wherein the compound is a small molecule.

11. The method of any one of claims 1-9, wherein the compound is an antibody.

12. The method of any one of claims 1-9, wherein the detectable protein is selected from the group consisting of β

-lactamase, chloramphenicol acetyltransferase, adenosine deaminase, aminoglycoside phosphotransferase, dihydrofolate reductase, hygromycin-B-phosphotransferase, thymidine kinase, β

-galactosidase and xanthine guaninephosphoribosyltransferase.

13. The method of any one of claims 1-9, wherein the reporter protein is alkaline phosphatase.

14. The method of any one of claims 1-9, wherein the mammalian Ob receptor has a cytoplasmic domain of 302 or 303 amino acids.

15. The method of any one of claims 1-9, wherein the Ob responsive regulatory element is IL-6 RE.

16. The method of any one of claims 1-9, wherein the Ob responsive regulatory element is HRRE.

17. The method of any one of claims 1-9, wherein the expression of the reporter protein is measured in the presence of leptin.

18. The method of any one of claims 1-9, wherein the expression of the reporter protein is measured in the absence of leptin.

19. The method of any one of claims 1-9, wherein the expression of the reporter protein is measured.

20. The method of any one of claims 1-9, wherein the expression of the mRNA encoding the reporter protein is measured.

2. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO;

42 from nucleotide 61 to nucleotide 3546, under conditions of hybridization at 65°

C. in 0.5 M NaHPO₄, 7% SDS, and 1 mM EDTA followed by washing at 68°

C. in 0.1×

SSC and 0.1% SDS.

3. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO;

3 from nucleotide 194 to nucleotide 3688.

4. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO;

42 from nucleotide 61 to nucleotide 3546.

5. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor comprises the amino acid sequence of SEQ ID NO;

4 from amino acid 21 to 1165.

6. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor comprises the amino acid sequence of SEQ ID NO;

41 from amino acid 24 to amino acid 1162.

7. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor comprises the amino acid sequence of SEQ ID NO;

2 from amino acid 23 to 837.

8. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor comprises the amino acid sequence of SEQ ID NO;

4 from amino acid 863 to 1165, inclusive.

9. A method for identifying candidate therapeutic agents for the treatment of a body weight disorder, comprising:

a) providing a cell that expresses a mammalian Ob receptor that is expressed on the cell surface, binds leptin, and includes a cytoplasmic domain having at least one tyrosine phosphorylation site, the cell comprising a reporter construct, the reporter construct comprising a sequence encoding a reporter protein, the sequence encoding the reporter protein being operably linked to an Ob receptor responsive regulatory element selected from the group consisting of IL-6 RE and HRRE;

b) contacting the cell with a test compound;

c) measuring the expression of the reporter protein or the mRNA encoding the reporter protein in the presence of the test compound;

d) selecting a test compound that increases or decreases the expression of the reporter protein or the mRNA encoding the reporter protein compared to the expression of the reporter protein or the mRNA encoding the reporter protein in the absence of the test compound;

e) identifying the selected test compound as a candidate therapeutic agent for treatment of a body weight disorder;

wherein the mammalian Ob receptor comprises the amino acid sequence of SEQ ID NO;

43 from amino acid 861 to 1162.